e-Therapeutics is a drug discovery and development company with a proprietary discovery platform based on advances in network pharmacology and chemical biology. The Company is applying its platform to the discovery of new drug candidates. The therapeutic focus of the Company’s discovery activity is in immuno-oncology, addressing drug resistance to targeted cancer therapies, and antivirals. The platform is yielding multiple, highly potent, selective and diverse molecules at much higher yields than is reported for conventional drug discovery. The Company has generated a variety of preclinical stage assets, including ETX1153c, a functionally resistance-less antibiotic; ETS2300, telomerase inhibition in anti-cancer; ETS3100, small molecule anti-TNFα; ETS2400, in Hedgehog pathway inhibition; and ETS5200, novel broad-spectrum antivirals. e-Therapeutics has also advanced selected drug candidates into clinical trials. A Phase IIb study of a drug candidate for major depressive disorder, ETS6103 is complete, plus Phase I clinical trials in cancer for ETS2101. The Company is well funded to advance its programmes. It is based at sites in Oxford and Newcastle, UK.